Table 1 Clinical characteristics of study subjects^a

Subject(n)

5

26

14

17

Age

34.40 ± 16.20

46.34 ± 12.83

41.35 ± 14.72

46.94 ± 13.00

Male (%)

60

54

57

47

Atopy (%)

100

85

90

84

BMI^#

24.61 ± 5.66

26.74 ± 4.54

25.43 ± 4.12

27.19 ± 5.11

MEF25

(1.9 ± 0.81)*

(0.69 ± 0.36)*

(1.34 ± 0.65)**

(0.51 ± 0.29)**

MEF50

(4.33 ± 1.32)*

(2.19 ± 1.16)*

(3.73 ± 1.05)**

(1.55 ± 0.74)**

MEF75

(8.02 ± 2.45)*

(4.49 ± 2.25)*

(7.22 ± 1.86)**

(3.28 ± 1.54)**

MEF(75/25)

(3.85 ± 1.28)*

(1.7 ± 0.89)*

(3.06 ± 1.02)**

(1.22 ± 0.62)**

FeNO (ppb)

(24.8 ± 12.38)*

(41.32 ± 24.66)*

30.86 ± 14.44

45.31 ± 28.38

IgE/(ng·mL^− 1)^b

148.9 ± 71.55

326.48 ± 393.57

277.93 ± 430.54

319.11 ± 340.12

Neutrophil^b (× 10⁹/L)

(3.27 ± 0.32)**

(5.06 ± 1.40)**

4.29 ± 1.71

5.16 ± 1.21

Eosinophils^b (× 10⁹/L)

0.34 ± 0.33

0.51 ± 0.65

0.31 ± 0.28

0.59 ± 0.74

ACT score

23 ± 2.65

21.43 ± 3.81

23 ± 1.89

20.75 ± 4.3

AQLQ score

82.67 ± 17.5

88.27 ± 15.1

90.2 ± 12.4

85.87 ± 16.88

VC

4.18 ± 0.75

3.66 ± 0.97

(4.13 ± 0.75)*

(3.43 ± 0.99)*

FVC

4.15 ± 0.75

3.64 ± 0.98

(4.11 ± 0.76)*

(3.42 ± 1.01)*

FEV1

(3.58 ± 0.75)*

(2.51 ± 0.85)*

(3.32 ± 0.66)**

(2.15 ± 0.75)**

FEV1/FVC

(102.88 ± 7.78)**

(81.12 ± 13.07)**

(97.01 ± 6.52)**

(74.45 ± 11.3)**

PEF

8.98 ± 2.07

7.01 ± 2.21

(8.71 ± 1.96)**

(6.17 ± 1.87)**